



SUPPORTING INNOVATION AND TECHNOLOGY TRANSFER IN ONCOLOGY

RIBOVAX

THERAPY



CONTEXT & BACKGROUND

There is a strong need to develop an optimized telomerase vaccine, as pointed in 2016 by a key opinion leader from the University of California in a review entitled: "A second chance for telomerase reverse transcriptase in anticancer immunotherapy".

The biotechnology company is developing a therapeutic vaccine for cancer immunotherapy, based on a first-in-class telomerase ribonucleoprotein.



INNOVATIVE COMPONENT & TECHNOLOGY

A conjugated protein-RNA vaccine (a telomerase ribonucleoprotein complex).



OBJECTIVES

To induce an immune response against any tumor that should allow extending the efficiency of immunocheckpoint inhibitors to almost all cancer patients.

SCOPE

A second chance for telomerase reverse transcriptase in anticancer immunotherapy

KEYWORDS

Telomerase immunotherapy





DEVELOPMENT & MATURATION STAGE

Proof of concept obtained in mice. Benchmark experiment to compare to the most recent competitor. Non-regular toxicity in monkeys also performed.



TARGET POPULATION

All cancers, as telomerase is reactivated in 90% of cancers in humans. First possible indications: Hepatocellular carcinoma (HCC), Prostate cancer, Bladder cancer, Glioblastoma(GBM), Head and Neck, Lung (NSCLC and SCLC), Renal(RCC)...



TARGET PROFILE

Immunotherapy



STRENGTHS & COMPETITIVE ADVANTAGES

This telomerase ribonucleoprotein has unprecedented immunological properties: it is self-vectored and self-adjuvanted. It activates the dual BCR/TLR signaling which orchestrates the break of tolerance in autoimmunity.



INDUSTRIAL APPLICATIONS & OPPORTUNITIES

Recombinant telomerase protein and telomerase ribonucleoprotein production. (Published in 2015)



INTELLECTUAL PROPERTY & PATIENT CO-OWNER(S)

The company has an exclusive worldwide license obtained from a first patent application owned by the University Paris Descartes. New IP in preparation.